Roger Williams Medical Center

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Roger Williams Medical Center sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 6 completed early-phase tilt top decile by trial count

Roger Williams Medical Center: 10 sponsored US clinical trials, none currently recruiting.

Roger Williams Medical Center sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Liver Metastases, with 2 trials.

Top-decile sponsor footprint

Roger Williams Medical Center ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

6 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (60.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 1

CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer

NCT02850536
COMPLETED Phase 1

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases

NCT02416466
COMPLETED Phase 1

CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells

NCT01373047
TERMINATED Phase 1

Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds

NCT01751282
TERMINATED Phase 1

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors

NCT01081808
TERMINATED Phase 1

Trial of Second Generation Designer T Cells in Colorectal Carcinoma

NCT00673322
TERMINATED Phase 1

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer

NCT00569296
COMPLETED Phase 1

Bioengineered Skin and Wound Healing

NCT00007280
COMPLETED Phase 1

Gene Therapy in Treating Patients With Cancer

NCT00004178
COMPLETED Phase 1

Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma

NCT00002681

Phase Distribution

PhaseTrial count
Phase 1 10

Therapeutic Areas

Liver Metastases 2
Leg Ulcers 1

How the Roger Williams Medical Center early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 6 completed (60%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Liver Metastases (2 trials), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Roger Williams Medical Center: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Roger Williams Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Roger Williams Medical CenterAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Roger Williams Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Roger Williams Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Roger Williams Medical Center page

10 registered trials is a research-attention snapshot, not an endorsement of Roger Williams Medical Center or any single study.

  • None of Roger Williams Medical Center's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Liver Metastases is the condition Roger Williams Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Liver Metastases trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Roger Williams Medical Center pipeline card: 10 registered trials from official public datasets.Report a data error.